| Date Filed | Type | Description |
| 09/27/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/17/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/16/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
4
| Serafini Tito (Chief Strategy Officer) has filed a Form 4 on Atreca, Inc.|
Txns:
| Sold 5,487 shares
@ $0.9522, valued at
$5.2k
|
|
| 08/04/2023 |
4
| CROSS HERB (CFO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Sold 5,487 shares
@ $0.9522, valued at
$5.2k
|
|
| 08/04/2023 |
4
| Gould Stephen E (Chief Scientific Officer) has filed a Form 4 on Atreca, Inc.|
Txns:
| Sold 4,076 shares
@ $0.9522, valued at
$3.9k
|
|
| 08/04/2023 |
4
| Courtney Phillips (General Counsel & Secretary) has filed a Form 4 on Atreca, Inc.|
Txns:
| Sold 4,076 shares
@ $0.9522, valued at
$3.9k
|
|
| 07/19/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/15/2023 |
4
| Rolfe Lindsey (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| Robinson William Hewitt (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| Ma Stacey (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| Lacey David L. (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| Brady Stephen R (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| BERGER FRANKLIN M (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| BALL KRISTINE M (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 06/15/2023 |
4
| ATWOOD BRIAN G (Director) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 12,000 options to buy
@ $1.18, valued at
$14.2k
|
|
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/11/2023 |
4
| Bishop Philippe C (Chief Medical Officer) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 350,000 options to buy
@ $1.37, valued at
$479.5k
|
|
| 01/11/2023 |
3
| Bishop Philippe C (Chief Medical Officer) has filed a Form 3 on Atreca, Inc. |
| 12/07/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update SAN CARLOS, Calif., Nov. 10, 2022 -- SAN CARLOS, Calif., November 10, 2022 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. "The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101,” said John Orwin, Chief Executive Officer of Atreca. “We remain encouraged by the association we see between clinical activity and target expression, the durability of the clinical activity observe..." |
|
|